Dynamics of tumor cell clonogen repopulation in a murine sarcoma treated with cyclophosphamide.
Experiments were performed to establish the extent and kinetics of tumor cell repopulation in a murine sarcoma, designated SA-NH, treated with cyclophosphamide (CY). Mice bearing 8-mm leg tumors were treated with 200 mg/kg CY which caused a transient tumor regression. Changes in the absolute clonogen content of tumors was determined by the change in TCD50 values (50% tumor control) obtained under hypoxic conditions of local tumor irradiation at different times after CY treatment until tumors regrew to the pretreatment size. For comparison, hypoxic TCD50 values were determined during the growth of tumors not treated with CY. CY greatly depleted tumors of clonogenic cells as manifested by the reduction in the control TCD50 value of 64.5 Gy to 32.8 Gy 1 day after CY treatment. The reduced TCD50 value remained unchanged for 2 weeks after treatment with CY, at which time the TCD50 began to rapidly increase, continuing until the end of the observation period of 21 days when tumors reached the pretreatment size. In contrast, there was a constant but slower increase in TCD50 values during the growth of tumors not treated with CY. The daily increase in TCD50 was more than twice as high in CY-treated than in CY-untreated tumors: 4.5 Gy/day versus 2.1 Gy/day. This implies that the rate of clonogen production in CY-treated tumors was twice as high as that of unperturbed tumors.(ABSTRACT TRUNCATED AT 250 WORDS)
Milas
L
L
Department of Experimental Radiotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Nakayama
T
T
Hunter
N
N
Jones
S
S
Lin
T M
TM
Yamada
S
S
Thames
H
H
Peters
L
L
D000818:Animals; D002452:Cell Count / Q000187:drug effects / Q000528:radiation effects; D002455:Cell Division / Q000187:drug effects / Q000528:radiation effects; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology*; D004307:Dose-Response Relationship, Radiation; D005260:Female; D000860:Hypoxia / Q000503:physiopathology; D007274:Injections, Intraperitoneal; D051379:Mice; D008809:Mice, Inbred C3H; D008815:Mice, Inbred Strains; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology / Q000528:radiation effects*; D011836:Radiation Tolerance / Q000187:drug effects; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012038:Regeneration / Q000187:drug effects / Q000528:radiation effects; D012513:Sarcoma, Experimental / Q000473:pathology* / Q000503:physiopathology
D002588:Cesium Radioisotopes; D003520:Cyclophosphamide